Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:

NCT ID: NCT02924272 Active, not recruiting - Multiple Myeloma Clinical Trials

Ixazomib Rollover Study

Start date: December 16, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.

NCT ID: NCT02916771 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Start date: October 2016
Phase: Phase 2
Study type: Interventional

This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.

NCT ID: NCT02911571 Active, not recruiting - Multiple Myeloma Clinical Trials

PRospective Multiple Myeloma Impact Study

PROMMIS
Start date: February 27, 2018
Phase: N/A
Study type: Interventional

This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.

NCT ID: NCT02909036 Active, not recruiting - Multiple Myeloma Clinical Trials

Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

Start date: September 2016
Phase: Phase 1
Study type: Interventional

Captisol Enabled Melphalan, is a new formulation of the standard of care melphalan chemotherapy that in packaged in an inactive substance that is believed to help the chemotherapy be more stable (meaning that it doesn't lose its effect or need to be administered quickly after being mixed). It may also have fewer side effects such as problems with important levels of body electrolytes such as potassium, phosphorous and magnesium; and cause less kidney and heart damage] than standard formulation melphalan. The purpose of this study is to determine if the investigators can achieve a certain level of Captisol Enabled Melphalan that would be best to use in treating Multiple Myeloma and AL Amyloidosis.

NCT ID: NCT02899052 Active, not recruiting - Multiple Myeloma Clinical Trials

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Start date: January 19, 2017
Phase: Phase 2
Study type: Interventional

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 of this study is currently enrolling.

NCT ID: NCT02892383 Active, not recruiting - Multiple Myeloma Clinical Trials

Quality of Life the Danish Multiple Myeloma Patients

QoL-MM
Start date: February 27, 2017
Phase:
Study type: Observational

The aim of the project is to improve quality of life for multiple myeloma patients in the future.

NCT ID: NCT02886065 Active, not recruiting - Clinical trials for Smoldering Multiple Myeloma

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Start date: March 7, 2017
Phase: Phase 1
Study type: Interventional

This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: - Lenalidomide - Citarinostat (CC-96241) - PVX-410

NCT ID: NCT02884102 Active, not recruiting - Multiple Myeloma Clinical Trials

MMRF Molecular Profiling Protocol

Start date: June 2015
Phase:
Study type: Observational

This protocol is now being used as screening for the MyDRUG study

NCT ID: NCT02863991 Active, not recruiting - Multiple Myeloma Clinical Trials

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Start date: January 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

ONC201 is an orally bioavailable first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. This is a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone to patients with relapsed/refractory multiple myeloma. Funding Source - FDA OOPD

NCT ID: NCT02861417 Active, not recruiting - Clinical trials for Myelodysplastic Syndrome

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Start date: August 5, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effect of busulfan, fludarabine phosphate, and post-transplant cyclophosphamide in treating patients with blood cancer undergoing donor stem cell transplant. Drugs used in chemotherapy, such as busulfan, fludarabine phosphate and cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy such as busulfan and fludarabine phosphate before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving cyclophosphamide after the transplant may stop this from happening. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them.